||WO||WO/2014/101903 - DENGUE VIRUS VACCINE COMPOSITION||03.07.2014||
||PCT/CU2013/000008||CENTRO DE INGENIRIA GENETICA Y BIOTECNOLOGIA||HERMIDA CRUZ, Lisset|
Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.
||WO||WO/2014/071894 - POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF||15.05.2014||
||PCT/CU2013/000007||CENTRO DE INMUNOLOGIA MOLECULAR||CORRIA OSORIO, Ángel de Jesús|
The invention relates to branches of biotechnology and, in particular, to mutated polypeptides of the TGFß molecule, the primary sequence of which is highly homologous with the sequence of human TGFß. These muteins lose their ability to interact with ALK5 but retain their ability to interact with the rest of the receptors that form part of the receptor complex (TßRII and TßRIII). In addition, they can antagonise the signalling of all of the natural variants of the TGFß ligands, dependent on the recruitment of ALK5 in the receptor complex, and they have an immunomodulatory effect. The invention also relates to pharmaceutical compositions comprising, as active principle, the disclosed polypeptides or fusion proteins and to the therapeutic use of the disclosed polypeptides, fusion proteins and pharmaceutical compositions owing to their immunomodulatory effect on diseases such as cancer, diseases associated with fibrosis and chronic infectious diseases.
||WO||WO/2014/067498 - CHIMERIC VACCINE ANTIGENS AGAINST HEPATITIS C VIRUS||08.05.2014||
||PCT/CU2013/000006||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||DUEÑAS CARRERA, Santiago|
The invention relates to chimeric vaccine antigens against hepatitis C virus (HCV), comprising selected regions of different antigens of said virus, which are placed in a pre-determined order inside the polypeptide. In addition, said chimeric antigens can include artificially-formed specific epitopes for auxiliary T cells. The chimeric antigens, and the resulting vaccine compositions, are suitable for use in medicine and the pharmaceutical industry, as well as being suitable for prophylactic and/or therapeutic use against HCV. The vaccine compositions of the invention generate a powerful, broad-spectrum immune response against different antigens of the virus, with a minimum number of components.
||WO||WO/2014/044230 - METHOD FOR OBTAINING 1-KESTOSE||27.03.2014||
||PCT/CU2013/000005||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||PÉREZ CRUZ, Enrique, Rosendo|
The invention relates to a method for obtaining 1-kestose on an industrial scale, using a recombinant fructosyltransferase (FTF) isolated from Festuca arundinacea, constitutively expressed in a non saccharolytic yeast host. According to the invention, the recombinant FTF of the sucrose:sucrose 1-fructosyltransferase (1-SSTrec) type is produced in a constitutive and stable manner and in high yields, both in the supernatant and in the cell sediment of the culture of a strain of Pichia pastoris. The invention also relates to a method for obtaining 1-SST on an industrial scale. The resulting recombinant enzyme is used for the mass enzymatic production of fructooligosaccharides (FOS), specifically 1-kestose, from sucrose. The method of the invention allows FOS conversion percentages greater than 55%, with 1-kestose being represented in more than 90%.
||WO||WO/2014/019555 - VESICLES WHICH INCLUDE EPIDERMAL GROWTH FACTOR AND COMPOSITIONS THAT CONTAIN SAME||06.02.2014||
||PCT/CU2013/000004||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||SANTANA MILIÁN, Héctor, Jesús|
The invention relates to vesicles which include epidermal growth factor (EGF), a cationic surface-active agent, and cholesterol or the derivatives thereof. The invention also discloses a method for preparing same using compressed fluid technology (FCs). The vesicles of the invention are useful in the production of drugs and cosmetic products, as well as in tissue engineering.
||WO||WO/2013/189467 - COMPOUNDS FROM THE FRUITS OF ACROCOMIA CRISPA AND ACROCOMIA ACULEATA AGAINST INFLAMMATION AND OXIDATIVE STRESS||27.12.2013||
||PCT/CU2013/000003||CENTRO NACIONAL DE INVESTIGACIONES CIENTIFICAS (CNIC)||GONZALES CANAVACIOLO, Victor Luis|
The invention relates to obtaining a novel active ingredient and to the method for obtaining same from the unripe or ripe fruits of Acrocomia crispa and/or Acrocomia aculeata, both from the Arecaceae family. The active ingredient can be used as a nutritional supplement, in cosmetic-therapeutic formulations or in pharmaceutical compositions for preventing and/or treating oxidative stress and inflammation. The ingredient includes a mixture of fatty acids (free and/or as acylglycerols or ethyl esters) having between 6 and 28 carbon atoms, mostly linear chain saturated having 8, 10, 12, 14, 16 and 18 carbon atoms and unsaturated having 16 and 18 carbon atoms. Said ingredient can also contain sterols and fatty alcohols having a high molecular weight.
||WO||WO/2013/143508 - METHOD FOR SIMULTANEOUS DETECTION, RECOVERY, IDENTIFICATION AND COUNTING OF MICROORGANISMS AND DEVICES FOR THE IMPLEMENTATION OF SAID METHOD||03.10.2013||
||PCT/CU2013/000002||CENTRO NACIONAL DE BIOPREPARADOS (BIOCEN)||RODRÍGUEZ MARTÍNEZ, Claudio|
The present invention describes a method and devices for the simultaneous detection, recovery, identification and counting of a plurality of microorganisms consisting in providing mixtures of nutrients specially selected from those that curtail the lag phase of growth in bacteria and moulds and which, together with fluorescent enzymatic, chromogenic or bioluminescent markers and other nutrient components or growth inhibitors, are embedded in three-dimensional structures or natural or artificial clays or ceramics with cavities of different dimensions and forms and specific surface areas of between 2 × 103 and 6 × 108 m2/m3.
||WO||WO/2013/127373 - RECOMBINANT ANTIBODIES HAVING DUAL SPECIFICITY FOR GANGLIOSIDES AND USE THEREOF||06.09.2013||
||PCT/CU2013/000001||CENTRO DE INMUNOLOGIA MOLECULAR||MORENO FRIAS, Ernesto|
The present invention relates to novel monoclonal antibodies and fragments of said antibodies, which have dual specificity and a high affinity for the gangliosides N-acetyl GM3 and N-glicolyl GM3, and which do not recognize other gangliosides. According to another aspect, the present invention relates to the use of said antibodies and the fragments thereof in tumor therapy, in which said tumors have a significant expression of any of the two antigens recognized by said antibodies, or a mixed expression of both antigens. The invention also relates to a use of said antibodies in the diagnosis of tumors that express at least one of the antigens.
||WO||WO/2013/113296 - COMPOSITION FROM LOBSTER HEMOCYTE EXTRACT FOR DETECTION OF LIPOPOLYSACCHARIDES, PEPTIDOGLYCANS AND 1,3-BETA-D-GLUCANS||08.08.2013||
||PCT/CU2012/000009||CENTRO DE INVESTIGACION Y DESARROLLO DE LOS MEDICAMENTOS(CIDEM)||PERDOMO MORALES, Rolando|
The present invention relates to the field of pharmaceuticals, chemistry and biotechnology and, in particular, to a method for preparing a composition for detecting and measuring the concentration of endotoxins or lipopolysaccharides, peptidoglycans and (1,3)-β-D-glucans, using a lobster hemocyte extract as starting material, to the modifications of the composition for increasing the sensitivity thereof, and to the methods for measuring endotoxins, peptidoglycans and (1,3)-β-D-glucans using said composition.
||WO||WO/2013/097834 - PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMOURS THAT EXPRESS EGFR AND GANGLIOSIDE N-GLYCOLYL GM3 (NEUGCGM3)||04.07.2013||
||PCT/CU2012/000007||CENTRO DE INMUNOLOGIA MOLECULAR||GONZÁLEZ PALOMO, Adys|
The invention relates to pharmaceutical composition for the treatment of malignant tumours, in particular tumours that express EGFR and N-glycolyl GM3 ganglioside targets, in order to enhance the therapeutic effect produced individually by therapies against said targets. The pharmaceutical compositions of the invention comprise antibodies and/or vaccines against each of the targets. In addition, the invention relates to the methods used to apply the compositions of the invention.